Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.
Checked against the public recordLast updated Sep 29, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- CellSight Technologies, Inc.
- Interventions being studied
- Drug: [18F]F AraG
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease. 2. RECIST measurable disease. 3. ECOG performance status of 0, 1 or 2. 4. Life expectancy \>/= 6 months at enrollment. Exclusion Criteria: 1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives. 2. Pregnant women or nursing mothers. 3. Patients with severe claustrophobia.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Palo Alto Veterans Institute of ResearchPalo Alto, California
- Sutter Cancer CenterSacramento, California
- Stony Brook UniversityStony Brook, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 29, 2023. Always confirm current availability with the study team.